TOFANE-GLOBAL
9.1.2023 18:01:40 CET | Business Wire | Press release
Tofane Global (TOFANE), the leading international communications solutions group, announces today the acquisition of DIMOCO Messaging, a leading global SMS aggregator based in Liechtenstein and Austria that delivers around two billion messages per year.
Business messaging or application-to-person (A2P) has grown into a global market worth an estimated 26.5 billion USD in 2022 and is predicted to reach 38 billion USD in 2025. With only 5% of companies using SMS A2P, business adoption of messaging is still in its infancy but is starting to surge as organizations come to realize that business SMS can become a key revenue generator for mobile operators.**
With this acquisition, TOFANE’s subsidiary iBASIS significantly accelerates its growth, doubling mobile services revenues to reach 20% of the company’s total revenues.
The addition of DIMOCO Messaging enhances iBASIS’s carrier-grade network infrastructure by adding more than 100 direct connections to mobile operators worldwide, ensuring the highest standards of speed and reliability for message termination.
iBASIS geographically expands its global commercial presence with DIMOCO Messaging’s offices located in Liechtenstein, Austria, Germany, and Serbia.
The acquisition also gives direct access to the enterprise market segment where DIMOCO Messaging has an established sales force to serve large financial institutions, leveraging new SMS Application Program Interfaces for system integration, APIs for rapid onboarding, and SMS campaign deployment.
Alexandre Pébereau, CEO, iBASIS, and Founder, CEO, TOFANE:
“TOFANE established itself as the first independent leader through acquisitions in international voice. Today, we are replicating our model in the similar but high-growth Business Messaging sector to build our second pillar. By adding DIMOCO Messaging and its senior team, we are boosting our growth path to become the preferred Tier One partner for our customers in mobile services.”
Cameron Calof, Managing Director, DIMOCO Messaging:
“We are very excited to join iBASIS. The company has built a Tier One reputation as preferred partner for global voice and mobile services. We share the same entrepreneurial spirit, business ethics, and customer-centric approach, and are committed to delivering a high level of quality and reliability for messaging worldwide. We are thrilled for our employees and customers as this acquisition opens a new era of possibilities and growth. iBASIS’ expertise and capabilities are undisputed, and we look forward to continuing to respond to the industry’s fast-growing market requirements together.”
Jeantet acted as exclusive legal adviser, Mazars as finance and tax adviser, Wagram Corporate Finance as financial adviser, and Global Telco Consult – GTC as technical adviser on this acquisition.
* DACH: Deutschland (D), Austria (A), and Switzerland (CH)
** Mobilesquared, Business Messaging Overview at MEF Business Messaging, June 2022
About Tofane Global
Tofane Global (TOFANE) is the leading communications solutions group enabling operators and digital players worldwide with their core strategies, performance, and transformation. Tofane Global acquired and successfully integrated seven companies in the global communications market, becoming the first independent player and innovation enabler across international Voice, Mobile Data and SMS messaging, Internet-of-Things, and 5G. As the result of the acquisitions of Altice Europe N.V., iBASIS, SFR, MEO (former Portugal Telecom), NOS, and Simfony, Tofane Global serves 1,000+ customers worldwide across its presence in 26 countries.
About DIMOCO Messaging
Before its acquisition by Tofane Global, DIMOCO Messaging was owned by BaseTech Ventures, an investment venture that invests in early-stage FinTech, internet, and technology start-ups. DIMOCO Messaging provides high quality, reliable A2P messaging products enabling our enterprise clients to communicate to their customers on a truly global scale. We leverage our relationships with Mobile Network Operators, CPaaS and in-country partners to offer clients direct connectivity, allowing them to optimize communication with their customers and employees seamlessly. DIMOCO Messaging, with offices in Liechtenstein, Austria, Germany, and Serbia, holds an MVNO license and operates a carrier-grade messaging platform with highest quality industry standards.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005012/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom